Humanigen (OTCQB:HGEN) has submitted a protocol synopsis
to the FDA related to its planned Phase 3 study of lenzilumab for the
prevention and treatment of cytokine storm in COVID-19 patients.
Hoth Therapeutics (NASDAQ:HOTH) inks an agreement with
Voltron Therapeutics subsidiary HaloVax to develop a COVID-19 vaccine
based on a self-assembling vaccine platform called VaxCelerate that
Voltron in-licensed from an entity at Massachusetts General Hospital.
Shares up 23% premarket.
Allogene Therapeutics (NASDAQ:ALLO) reports that collaboration partner Servier has suspended recruitment in the Phase 1 PALL and CALM studies evaluating UCART19 in ALL patients citing disruptions from the global pandemic.
Voyageur Pharmaceuticals Ltd. (OTC:VYYRF) has postponed the
filing of its fiscal 2019 financial statements (year ending November
30) until on or about April 3 due pandemic-related disruptions
https://seekingalpha.com/news/3555818-covidminus-19-actions-healthcare
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.